EUVIMEDEUVIMED entdecken
Crossref

Differences of longitudinal plasma biomarkers between single memory domain and multidomain subjective cognitive decline: Evidence from SILCODE

Min Wei, Xianfeng Yu iD, Shimin Hu iD, Wenjing Hu, Rong Shi iD, Min Wang, Jiayi Zhong, Qi Zhang, Ying Zhang iD, Chenyang Li iD, Ziyan Song iD, Jiehui Jiang iD und 1 weitere

Journal of Alzheimer’s Disease · 2025

DOI: 10.1177/13872877241309105 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, 2025. Verfasst von Min Wei und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Memory. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: National Natural Science Foundation of China, STI2030-Major Projects, Sino-German Cooperation Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Plasma biomarkers demonstrated potential in identifying amyloid pathology in early Alzheimer's disease. Different subtypes of subjective cognitive decline (SCD) may lead to different cognitive impairment conversion risks.

Objective

To investigate the differences of plasma biomarkers in SCD subtypes individuals, which were unclear.

Methods

The 347 individuals were involved, including 93 normal controls (NC), 76 single memory domain SCD (sd-SCD), 79 multidomain SCD (md-SCD), 55 mild cognitive impairment and 44 dementia. We investigated plasma biomarkers (Aβ 42/40 , p-tau181, p-tau217, NfL, and GFAP) and neuropsychological scales in the baseline and follow-up. The Kaplan-Meier survival analysis and Cox proportional hazards model were performed to investigate the risk of cognitive decline conversion. The t-test, Mann-Whitney U and multiple linear regression analysis were employed to evaluate the rate of change and correlation between PET-SUVR and plasma biomarker change.

Results

In cognitively normal subjects, md-SCD exhibited lower Aβ 42/40 and higher p-tau181 and p-tau217 levels. Kaplan-Meier survival analysis revealed that md-SCD group exhibited a higher risk of cognitive decline conversion compared to NC and sd-SCD. Within SCD subgroups, those with positive GFAP status showed higher conversion risk than negative. In the Cox model, the risk of conversion in the md-SCD group was 2.77 times that of sd-SCD. The md-SCD group demonstrated a faster rate of Aβ 42/40 decline than sd-SCD.

Conclusions

The study utilized plasma biomarkers to highlight the significance of staging in SCD. In cognitively normal subjects, md-SCD presents a higher risk of cognitive decline than sd-SCD, providing a valuable reference and convenient tool for early identification of individuals at risk for AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cognitive DysfunctionMemoryHumansBiomarkersMaleFemaleAgedtau ProteinsAmyloid beta-PeptidesMiddle AgedLongitudinal StudiesNeuropsychological TestsPeptide FragmentsAlzheimer DiseaseDisease ProgressionPositron-Emission TomographyGlial Fibrillary Acidic Protein

Stichwörter der Autor:innen

Alzheimer's diseasebiomarkerbloodsubjective cognitive decline

Substanzen

Biomarkerstau ProteinsAmyloid beta-PeptidesPeptide Fragmentsamyloid beta-protein (1-42)Glial Fibrillary Acidic Protein

Autor:innen und Institutionen

  • Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China.
  • Institute of Biomedical Engineering, School of Life Sciences, Shanghai University, Shanghai, China.
  • State Key Laboratory of Digital Medical Engineering, Key Laboratory of Biomedical Engineering of Hainan Province, School of Biomedical Engineering, Hainan University, Hainan, China.
  • Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen, China.
  • National Clinical Research Center for Geriatric Diseases, Beijing, China.
  • The Central Hospital of Karamay, Xinjiang, China.

ORCID-Profile: Xianfeng Yu, Shimin Hu, Rong Shi, Ying Zhang, Chenyang Li, Ziyan Song, Jiehui Jiang, Ying Han

Förderung

  • National Natural Science Foundation of China
  • STI2030-Major Projects
  • Sino-German Cooperation Grant
  • Shenzhen Bay Scholars Program and Tianchi Scholars Program

Zitieren

APA

Wei, M., Yu, X., Hu, S., Hu, W., Shi, R., Wang, M., Zhong, J., Zhang, Q., Zhang, Y., Li, C., Song, Z., Jiang, J., & Han, Y. (2025). Differences of longitudinal plasma biomarkers between single memory domain and multidomain subjective cognitive decline: Evidence from SILCODE. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877241309105

Vancouver

Wei M, Yu X, Hu S, Hu W, Shi R, Wang M, et al. Differences of longitudinal plasma biomarkers between single memory domain and multidomain subjective cognitive decline: Evidence from SILCODE. Journal of Alzheimer’s Disease. 2025. doi:10.1177/13872877241309105

BibTeX
@article{Wei2025,
  author = {Wei, Min and Yu, Xianfeng and Hu, Shimin and Hu, Wenjing and Shi, Rong and Wang, Min and Zhong, Jiayi and Zhang, Qi and Zhang, Ying and Li, Chenyang and Song, Ziyan and Jiang, Jiehui and Han, Ying},
  title = {Differences of longitudinal plasma biomarkers between single memory domain and multidomain subjective cognitive decline: Evidence from SILCODE},
  journal = {Journal of Alzheimer’s Disease},
  year = {2025},
  doi = {10.1177/13872877241309105}
}
Kostenlos starten →